In vitro data can be used to accelerate the approval of drugs that target specific disease-causing mutations for additional subpopulations of patients with rare diseases such as cystic fibrosis.

中文翻译：

---

FDA OKS首先在体外路线扩大审批

体外数据可用于加速针对特定疾病致突变的药物的批准，这些药物可用于患有罕见疾病（如囊性纤维化）的患者的其他亚群。